帕博利珠单抗治疗高肿瘤突变负荷转移性乳腺癌:TAPUR研究结果
PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets.…
要点
- 帕博利珠单抗单药在经重度治疗的HTMB转移性乳腺癌中显示抗肿瘤活性。
- 疾病控制率37%,客观缓解率21%,中位无进展生存期10.6周。
- 无进展生存期与肿瘤突变负荷之间未见关系。
核心结论
- 帕博利珠单抗单药在经重度治疗的高肿瘤突变负荷转移性乳腺癌患者中具有抗肿瘤活性。
研究设计与样本
- TAPUR研究为II期篮式试验,采用Simon两阶段设计,主要终点为疾病控制(客观缓解或至少16周疾病稳定)。
主要发现
- 中位无进展生存期为10.6周(95%CI 7.7-21.1),中位总生存期为30.6周(95%CI 18.3-103.3)。
- 未观察到无进展生存期与肿瘤突变负荷之间的关系。
- 5例患者发生至少1次与帕博利珠单抗至少可能相关的严重不良事件或3级不良事件,与产品标签一致。
临床怎么用
- 研究结果支持FDA近期批准帕博利珠单抗用于无替代治疗方案的不可切除或转移性高肿瘤突变负荷实体瘤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Results in a cohort of patients with metastatic breast cancer (mBC) with high tumor mutational burden (HTMB) treated with pembrolizumab are reported. METHODS: Patients with advanced mBC received standard doses of either 2 mg/kg or 200 mg infusions of pembrolizumab every 3 weeks. Simon's two-stage design was used with a primary study end point of disease control (DC) defined as objective response or stable disease of at least 16 weeks duration. If two or more patients in stage I achieved DC, the cohort would enroll 18 additional patients in stage II. Secondary end points include progression-free survival (PFS), overall survival, and safety. RESULTS: Twenty-eight patients were enrolled from October 2016 to July 2018. All patients' tumors had HTMB ranging from 9 to 37 mutations/megabase. DC and objective response were noted in 37% (95% CI, 21 to 50) and 21% of patients (95% CI, 8 to 41), respectively. Median PFS was 10.6 weeks (95% CI, 7.7 to 21.1); median overall survival was 30.6 weeks (95% CI, 18.3 to 103.3). No relationship was observed between PFS and tumor mutational burden. Five patients experienced ≥ 1 serious adverse event or grade 3 adverse event at least possibly related to pembrolizumab consistent with the product label. CONCLUSION: Pembrolizumab monotherapy has antitumor activity in heavily pretreated patients with mBC characterized by HTMB. Our findings support the recent US Food and Drug Administration approval of pembrolizumab for treatment of patients with unresectable or metastatic solid tumors with HTMB without alternative treatment options.
引用
- Alva AS, Mangat PK, Garrett-Mayer E, et al. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021. PMID: 33844595. doi:10.1200/JCO.20.02923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。